A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia
Key claim: A Phase 1 trial is evaluating STP938 monotherapy for safety and platelet-count control in adults with high-risk essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Abstract
The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are:
- Does STP938 control platelet counts
- Does STP938 control platelet counts without inducing unwanted side effects
Participants will:
- Take STP938 every day for up to 12 months.
- Visit the clinic once every week for the first month, then every 2 weeks for checkups and tests.
- Complete a questionnaire about symptoms once a month.
Why this matters
High-risk ET patients who fail or cannot tolerate hydroxyurea remain an underserved population, with current options limited to anagrelide and interferons. STP938 represents a novel mechanism entering this space, and its Phase 1 development specifically targets the HU-resistant/intolerant ET subtype niche. If successful, it would diversify the second-line cytoreductive landscape that has recently been shaped by ropeginterferon’s SURPASS-ET data.